When was Yondelis approved?
Development Timeline for Yondelis
| Date | Article |
|---|---|
| Oct 23, 2015 | Approval FDA Approves Yondelis (trabectedin) for the Treatment of Specific Soft Tissue Sarcomas |
| Feb 3, 2015 | U.S. FDA Grants Priority Review for Yondelis (trabectedin) for the Treatment of Patients with Advanced Soft Tissue Sarcoma |
Where is trabectedin located?
At a time when drugs are being designed for specific targets in oncology, Trabectedin is a naturally occurring compound found in a sea squirt called Ecteinascidiaturbinate(E. turbinate).
What is the price of Yondelis?
The cost for Yondelis intravenous powder for injection 1 mg is around $3,243 for a supply of 1 powder for injection, depending on the pharmacy you visit….Intravenous Powder For Injection.
| Quantity | Per unit | Price |
|---|---|---|
| 1 | $3,243.06 | $3,243.06 |
What is the FDA’s approval for trabectedin (Yondelis®)?
On October 23, the Food and Drug Administration (FDA) approved trabectedin (Yondelis®) for the treatment of two subtypes of soft tissue sarcomas: liposarcoma and leiomyosarcoma. The approval is for patients whose cancers are advanced or cannot be removed by surgery…
Is Yondelis FDA approved for liposarcoma?
The FDA approved YONDELIS based on evidence from a clinical trial of 518 patients with liposarcoma and leiomyosarcoma . The trial was conducted in 85 sites in 4 countries (Australia, Brazil, New Zealand, and the United States). Ninety-four percent of the patients were enrolled in U.S. sites.
What is Yondelis used to treat?
Refer to the YONDELIS Prescribing Information for complete information. What is the drug for? YONDELIS is a drug used to treat patients with liposarcoma and leiomyosarcoma that cannot be removed by surgery (unresectable) or is advanced (metastatic).
Does Yondelis work differently in men and women?
Sex: YONDELIS was similarly effective in men and women. Race: The majority of patients in the trial were white. Differences in response to YONDELIS could not be determined. Age: The majority of patients in the trial were below 65 years of age. Differences in response to YONDELIS could not be determined.